Kevin Oeffinger, MD, is a family physician, a member of the Duke Cancer Institute (DCI), the founding Director of the DCI Center for Onco-Primary Care, and Director of the DCI Supportive Care and Survivorship Center. Prior to joining Duke in April 2017, Dr. Oeffinger was the Director of the Cancer Survivorship Center at Memorial Sloan Kettering Cancer Center. He has a long-standing track record of NIH-supported research in cancer screening and survivorship and has served in a leadership capacity in various cancer-focused and primary care-focused national committees and organizations, including the American Society of Clinical Oncology, the American Cancer Society, and the American Academy of Family Physicians.
The three-fold mission of the DCI Center for Onco-Primary Care are are to: (1) deliver evidence-based, patient-centered, personalized health care across the cancer continuum by enhancing the interface between cancer specialists and primary care clinicians; (2) conduct innovative research with cutting-edge technology that can be translated to the community setting; and (3) train and educate the next generation of clinicians and researchers to extend this mission.
In the summer of 2017, Dr. Oeffinger will begin seeing patients at DCI who are cancer survivors and have a high risk of future cancers or have multiple medical problems related to their previous cancer therapy.
Education and Training
- Advanced Research Training, Epidemiology And Genetics, Radiation Epidemiology, National Cancer Institute, 1999 - 2000
- Family Medicine Academic Fellowship, Baylor College of Medicine, 1987 - 1988
- Family Medicine Internship and Residency, Baylor College of Medicine, 1984 - 1987
- M.D., University of Texas Health Science Center San Antonio, 1984
- EMPOWER Study: Promoting BC Screening in Women Who Survived Childhood Cancer
- Improving Treatment of Cardiovascular Risk Factors in Childhood Cancer Survivors
- Childhood Cancer Survivor Study (CCSS)
- Generic Testing to Guide Pediatric Cancer Care and Follow Up: Using Anthracycline-associated Cardiac Toxicity as a Model for the Future
- Exercise and QUality diet After Leukemia